|Pfizer Wins EU Approval for $15 Billion Hospira Buy; CEL-SCI Reports Record Monthly Patient Enrollment in July|
|By Marilyn Mullen|
|Wednesday, 05 August 2015 18:35|
Below is a look at some of the headlines for companies that made news in the healthcare sector on August 5, 2015.
U.S. drugmaker Pfizer (PFE: NYSE) gained European Union antitrust approval on Tuesday for its proposed $15 billion acquisition of U.S. rival Hospira after pledging to sell some drugs to allay competition concerns.
"The approval is conditional on Pfizer divesting certain sterile injectable drugs, as well as its infliximab biosimilar drug, which is currently under development," the European Commission said.
The deal will boost Pfizer's portfolio of generic injectable drugs and copies of biotech medicines.
CEL-SCI Corporation (NYSE MKT: CVM) announced in July it has enrolled 33 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer. This marks a new monthly record. Total study enrollment now stands at 521 patients as of July 31, 2015 in the world's largest Phase 3 study in head and neck cancer.
"We continue to deliver record monthly enrollment numbers, which are in line with our expectations and bring us to over 500 patients enrolled in our Phase 3 study as of the end of July," stated CEL-SCI Chief Executive Officer Geert Kersten.
A total of 880 patients are expected to be enrolled, through approximately 100 clinical centers in over 20 countries.
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has it has issued a letter to shareholders providing an update on the progress it has made to advance its two drug candidates, Iomab-B and Actimab-A, towards commercialization.
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its financial results and business highlights for the second quarter of 2015.
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, Cushing's disease and autoimmune and inflammatory diseases, today provided recent corporate highlights and reported its financial results for the second quarter ended June 30, 2015.
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the Canaccord Genuity 35th Annual Growth Conference on August 12, 2015 at the InterContinental in Boston, Massachusetts.
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the second quarter and year to date ended June 30, 2015 and provided a corporate update on its clinical development plans for the remainder of 2015.
Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), today announced its second quarter 2015 unaudited financial results and provided a corporate update.
CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, today reported financial results for the quarter and six months ended June 30, 2015, and provided a business update.
CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that the Company has initiated its first clinical site for its Phase 3 trial.
ERBA Diagnostics, Inc. (NYSE MKT:ERB) will report its second quarter 2015 financial results after market close today, Wednesday, August 5, 2015.
ERBA Diagnostics, Inc. (NYSE MKT:ERB), a fully integrated in vitro diagnostics company, today announced financial results for the quarter and six months ended June 30, 2015.
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the development of programmed cellular immunotherapeutics for the treatment of severe, life-threatening diseases, today announced its financial results for the second quarter ended June 30, 2015, and recent corporate and clinical highlights.
FBR & Co. (Nasdaq:FBRC), a leading investment bank serving the middle market, announced its Second Annual Healthcare Conference. The event will be held on Wednesday, September 9, 2015 at the Four Seasons Hotel in Boston, Massachusetts.
Geron Corporation (Nasdaq:GERN) today reported financial results for the second quarter ended June 30, 2015.
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications announced it has joined the Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine as an official technology partner.
Juno Therapeutics, Inc. (NASDAQ:JUNO) will announce financial results for the second quarter of 2015 on Wednesday, August 12, 2015 after the close of U.S.-based financial markets.
LDR Holding Corporation (NASDAQ:LDRH), a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders, today reported its financial results for the second quarter ended June 30, 2015.
LHC Group, Inc. (NASDAQ:LHCG), a national provider of home health, hospice, and community-based and comprehensive post-acute healthcare services, today announced its financial results for the three months and six months ended June 30, 2015.
MTBC (Nasdaq:MTBC), a leading provider of proprietary, healthcare information technology solutions today announced that SoftCare Solutions, its clearinghouse division, has been granted full accreditation by the Electronic Healthcare Network Accreditation Commission (EHNAC).
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and CEO, will present at the Wedbush PacGrow Healthcare Conference.
OpGen, Inc. (NASDAQ:OPGN), today announced that financial results for the company's second quarter ended June 30, 2015 will be released Thursday, August 13, 2015 following the close of market.
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the three and six months ended June 30, 2015.
Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT) (TSX:NTB) and Acasti Pharma Inc. (NASDAQ:ACST) (TSX-V:APO), a Neptune subsidiary, announce the appointment of Mario Paradis as Chief Financial Officer (CFO), starting August 24, 2015.
Pacific Biosciences of California, Inc. (NASDAQ:PACB) today reported a 118% increase in revenue with $24.9 million for the second quarter ended June 30, 2015, compared to $11.4 million for the second quarter of 2014.
Tornier N.V. (NASDAQ:TRNX), a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, reported today its financial results for the second quarter ended June 28, 2015.
TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced its financial results for the second quarter ended June 30, 2015.
WaferGen Bio-systems, Inc. (Nasdaq:WGBS) announced today its financial results for the second quarter and six months ended June 30, 2015.
Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced that Thomas Hughes, Ph.D., Chief Executive Officer, will present at the Canaccord Genuity 35th Annual Growth Conference on Wednesday, August 12, 2015 at 8:30 a.m. ET in the New York Room at the InterContinental Hotel in Boston.